PDF(Pubmed)
Abstract：
Cervical cancer is the fourth most common cancer in women. Advanced stage and metastatic disease are often associated with poor clinical outcomes. This substantiates the absolute necessity for high-throughput diagnostic and treatment platforms that are patient and tumour specific. Cervical cancer treatment constitutes multimodal intervention. Systemic treatments such as chemotherapy and/or focal radiotherapy are typically applied as neoadjuvant and/or adjuvant strategies. Cisplatin constitutes an integral part of standard cervical cancer treatment approaches. However, despite initial patient response, de novo or delayed/acquired treatment resistance is often reported, and toxicity is of concern. Chemotherapy resistance is associated with major alterations in genomic, metabolomic, epigenetic and proteomic landscapes. This results in imbalanced homeostasis associated with pro-oncogenic and proliferative survival, anti-apoptotic benefits, and enhanced DNA damage repair processes. Although significant developments in cancer diagnoses and treatment have been made over the last two decades, drug resistance remains a major obstacle to overcome.
Despite advances in treatment, the disease’s advanced stages and spread to other parts of the body often lead to poor outcomes. This highlights the urgent need for better diagnostic and treatment methods tailored to each patient and their specific tumour. Treatment for cervical cancer usually involves a combination of therapies. Chemotherapy and focused radiation therapy are commonly used before or after surgery to improve outcomes. However, some patients develop resistance to these treatments, either from the start or after initially responding to therapy. This resistance can make treatment less effective and increase the risk of side effects. Chemotherapy resistance is often linked to changes in the genes and proteins of cancer cells. These changes disrupt the normal balance within the cells, making them more prone to grow and survive, resist cell death, and repair DNA damage caused by treatment. Despite progress in cancer research and treatment, drug resistance remains a significant challenge. This review aims to explore how acquired genetic mutations contribute to drug resistance in cervical cancer. By understanding these mutations better, researchers and clinicians in low- to middle-income countries can develop more effective treatment strategies to improve outcomes for patients.
Despite advances in treatment, the disease’s advanced stages and spread to other parts of the body often lead to poor outcomes. This highlights the urgent need for better diagnostic and treatment methods tailored to each patient and their specific tumour. Treatment for cervical cancer usually involves a combination of therapies. Chemotherapy and focused radiation therapy are commonly used before or after surgery to improve outcomes. However, some patients develop resistance to these treatments, either from the start or after initially responding to therapy. This resistance can make treatment less effective and increase the risk of side effects. Chemotherapy resistance is often linked to changes in the genes and proteins of cancer cells. These changes disrupt the normal balance within the cells, making them more prone to grow and survive, resist cell death, and repair DNA damage caused by treatment. Despite progress in cancer research and treatment, drug resistance remains a significant challenge. This review aims to explore how acquired genetic mutations contribute to drug resistance in cervical cancer. By understanding these mutations better, researchers and clinicians in low- to middle-income countries can develop more effective treatment strategies to improve outcomes for patients.
摘要：
宫颈癌是女性第四大最常见的癌症。晚期和转移性疾病通常与不良的临床结果相关。这证实了对患者和肿瘤特异性的高通量诊断和治疗平台的绝对必要性。宫颈癌治疗构成多模式干预。全身治疗如化疗和/或局灶性放疗通常作为新辅助和/或辅助策略应用。顺铂构成标准宫颈癌治疗方法的组成部分。然而,尽管最初的患者反应，从头或延迟/获得性治疗抗性经常被报道，毒性令人担忧。化疗耐药与基因组的重大改变有关，代谢组学，表观遗传和蛋白质组景观。这导致与致癌和增殖生存相关的不平衡的体内平衡。抗凋亡的好处，和增强DNA损伤修复过程。尽管在过去的二十年中，癌症的诊断和治疗取得了重大进展，抗药性仍然是需要克服的主要障碍。
尽管在治疗方面取得了进展,这种疾病的晚期和扩散到身体的其他部位往往会导致不良的结果。这凸显了迫切需要针对每个患者及其特定肿瘤定制的更好的诊断和治疗方法。宫颈癌的治疗通常涉及治疗的组合。化疗和聚焦放射治疗通常在手术前或手术后使用，以改善预后。然而,一些患者对这些治疗产生抗药性，从治疗开始或最初反应后。这种耐药性会使治疗效果降低，并增加副作用的风险。化疗抗性通常与癌细胞的基因和蛋白质的变化有关。这些变化破坏了细胞内的正常平衡，使它们更容易生长和生存，抵抗细胞死亡,修复由治疗引起的DNA损伤。尽管癌症研究和治疗取得了进展，耐药性仍然是一个重大挑战。本文旨在探讨获得性基因突变对宫颈癌耐药的影响。通过更好地理解这些突变，中低收入国家的研究人员和临床医生可以制定更有效的治疗策略,以改善患者的预后.
尽管在治疗方面取得了进展,这种疾病的晚期和扩散到身体的其他部位往往会导致不良的结果。这凸显了迫切需要针对每个患者及其特定肿瘤定制的更好的诊断和治疗方法。宫颈癌的治疗通常涉及治疗的组合。化疗和聚焦放射治疗通常在手术前或手术后使用，以改善预后。然而,一些患者对这些治疗产生抗药性，从治疗开始或最初反应后。这种耐药性会使治疗效果降低，并增加副作用的风险。化疗抗性通常与癌细胞的基因和蛋白质的变化有关。这些变化破坏了细胞内的正常平衡，使它们更容易生长和生存，抵抗细胞死亡,修复由治疗引起的DNA损伤。尽管癌症研究和治疗取得了进展，耐药性仍然是一个重大挑战。本文旨在探讨获得性基因突变对宫颈癌耐药的影响。通过更好地理解这些突变，中低收入国家的研究人员和临床医生可以制定更有效的治疗策略,以改善患者的预后.
